ALX Oncology grants 800,000 stock options
ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ALX Oncology Holdings Inc. reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options covering 800,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
According to the vesting terms, one-fourth of the options vest on April 13, 2027 and the remaining options vest in equal monthly installments over the following three years. After this grant, Knight holds 800,000 stock options directly.
Insider Trade Summary
Grant/Award: 800,000 shares
Grant/Award
1 txn
Insider
Knight Jeff E.
Role
Chief Dev & Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 800,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 800,000 contracts (Direct)
Footnotes (1)
- F1. One-fourth of the shares subject to the option vest on April 13, 2027 and 1/48th vest monthly thereafter.
Key Figures
Options granted: 800,000 stock options
Exercise price: $1.68 per share
Underlying shares: 800,000 shares
+3 more
6 metrics
Options granted
800,000 stock options
Grant to Chief Dev & Operating Officer on 2026-04-16
Exercise price
$1.68 per share
Exercise price for underlying Common Stock
Underlying shares
800,000 shares
Common Stock underlying the granted options
Vesting cliff
25% on April 13, 2027
One-fourth of options vest on this date
Ongoing vesting
1/48 monthly thereafter
Remaining options vest in equal monthly installments
Expiration date
April 15, 2036
Final expiration of the stock option grant
Key Terms
Stock option (right to buy), Common Stock, Grant, award, or other acquisition, vest, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest financial
"One-fourth of the shares subject to the option vest on April 13, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
expiration date financial
"expiration_date: 2036-04-15T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ALXO report for Jeff E. Knight?
ALX Oncology reported that Chief Development & Operating Officer Jeff E. Knight received a grant of stock options for 800,000 shares of Common Stock. These options were awarded at an exercise price of $1.68 per share and represent a compensation-related acquisition, not an open-market trade.
What is the exercise price of Jeff E. Knight’s new ALXO stock options?
The granted stock options have an exercise price of $1.68 per share for the underlying Common Stock. This means Knight can buy up to 800,000 shares at $1.68 once the options vest, regardless of the future market price, until the options expire.
How do the 800,000 ALXO stock options granted to Jeff E. Knight vest?
The options vest over time. One-fourth of the 800,000 options vest on April 13, 2027, with the remaining three-fourths vesting in equal monthly installments thereafter. This schedule encourages long-term alignment between Knight and ALX Oncology’s performance and retention over several years.
When do Jeff E. Knight’s ALXO stock options expire?
The stock options granted to Jeff E. Knight expire on April 15, 2036. Until that expiration date, and subject to the vesting schedule, Knight may choose to exercise vested options to purchase ALX Oncology Common Stock at the fixed exercise price of $1.68 per share.
How many ALXO stock options does Jeff E. Knight hold after this grant?
Following this award, Jeff E. Knight holds a total of 800,000 stock options directly. All of these options relate to ALX Oncology Common Stock, carry an exercise price of $1.68 per share, and are subject to the time-based vesting and final expiration date disclosed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates